Published mark
Oruka Therapeutics, Inc.
NASDAQ: ORKA. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:b4b36520-180e-4a7b-ac27-14a6ef7429c7
- SEC CIK
- 0000907654
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 24, 2026
- Newest evidence
- Apr 17, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Lawrence KleinPresident and Chief Executive Officer
- Chair
- Samarth Kulkarni
- Independent
- Not published6 directors published
- Published claims
- 292 distinct sources
- Evidence records
- 40 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 4 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Cameron Turtle seat on Oruka Therapeutics, Inc., effective 2026-04-17.
EffectiveEffective Apr 17, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Senior Vice President, Finance and Treasurer | Arjun Agarwal | Not captured | unknown | Source reportedE2 |
| Chief Medical Officer | Joana Goncalves | Not captured | unknown | Source reportedE2 |
| Chief Operating Officer | Laura Sandler | Not captured | unknown | Source reportedE2 |
| President and Chief Executive Officer | Lawrence Klein | Not captured | unknown | Source reportedE2 |
| General Counsel and Corporate Secretary | Paul Quinlan | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence6 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Cameron Turtle | Independence not published | 2026 | Audit CommitteeCompensation Committee | Source reportedE3 |
| Carl Dambkowski | Independence not published | 2026 | Audit Committee | Source reportedE3 |
| Chris Martin | Independence not published | 2026 | Audit CommitteeCompensation Committee, chair | Source reportedE3 |
| Kristine Ball | Independence not published | 2026 | Audit Committee, chairNominating and Corporate Governance Committee | Source reportedE3 |
| Paul Quinlan | Independence not published | 2026 | None published | Source reportedE3 |
| Peter Harwin | Independence not published | 2026 | Compensation CommitteeNominating and Corporate Governance Committee, chair | Source reportedE3 |
| Lawrence Klein | Not independent | Not published | None published | Source reportedE2 |
| Samarth Kulkarni | IndependentChair | Not published | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | Kristine Ball | Kristine Ball, Cameron Turtle, Carl Dambkowski, Chris Martin | Not described in the published record |
| Compensation Committee | Chris Martin | Chris Martin, Cameron Turtle, Peter Harwin | Not described in the published record |
| Nominating and Corporate Governance Committee | Peter Harwin | Peter Harwin, Kristine Ball | Not described in the published record |
Committee RecordAudit Committee: Chair Kristine Ball; Members Kristine Ball (Chair); Cameron Turtle; Carl Dambkowski; Chris Martin
Committee AppointmentKristine Ball: chair, Audit Committee
Committee AppointmentCameron Turtle: member, Audit Committee
Committee AppointmentCarl Dambkowski: member, Audit Committee
Committee AppointmentChris Martin: member, Audit Committee
Committee RecordCompensation Committee: Chair Chris Martin; Members Chris Martin (Chair); Cameron Turtle; Peter Harwin
Committee AppointmentChris Martin: chair, Compensation Committee
Committee AppointmentCameron Turtle: member, Compensation Committee
Committee AppointmentPeter Harwin: member, Compensation Committee
Committee RecordNominating and Corporate Governance Committee: Chair Peter Harwin; Members Peter Harwin (Chair); Kristine Ball
Committee AppointmentPeter Harwin: chair, Nominating and Corporate Governance Committee
Committee AppointmentKristine Ball: member, Nominating and Corporate Governance Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerLawrence Klein, President and Chief Executive Officer
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingORKA (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 24, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameOruka Therapeutics, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Arjun AgarwalSenior Vice President, Finance and Treasurercompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:13
- Joana GoncalvesChief Medical Officercompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:14
- Laura SandlerChief Operating Officercompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:15
- Lawrence KleinPresident and Chief Executive Officer; Chief Executive Officer and Directorcompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:16, company:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:10
- Paul QuinlanGeneral Counsel and Corporate Secretary; Directorcompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:17, company:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:11
- Cameron TurtleDirectorcompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:6
- Carl DambkowskiDirectorcompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:7
- Chris MartinDirectorcompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:8
- Kristine BallDirectorcompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:9
- Peter HarwinDirectorcompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:12
- Samarth KulkarniDirector and Chaircompany:b4b36520-180e-4a7b-ac27-14a6ef7429c7:leadership_role:5
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 4 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 24, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 17, 2026. Retrieved Sep 12, 2026. Cited by 7 Claims.
- E3sec proxy. Published Apr 17, 2026. Retrieved Sep 2, 2026. Cited by 6 Claims.
- E4governance_people_committees. sec proxy. Cited by 12 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 24, 2026- Cameron Turtle seat on Oruka Therapeutics, Inc., effective 2026-04-17.
- Carl Dambkowski seat on Oruka Therapeutics, Inc., effective 2026-04-17.
- Chris Martin seat on Oruka Therapeutics, Inc., effective 2026-04-17.
- Kristine Ball seat on Oruka Therapeutics, Inc., effective 2026-04-17.
- Paul Quinlan seat on Oruka Therapeutics, Inc., effective 2026-04-17.
- Peter Harwin seat on Oruka Therapeutics, Inc., effective 2026-04-17.